Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

The Global Offering, for approximately 10% of the Company’s share capital, is aimed at international institutional investors, via a Private Placement through an accelerated book-building process. The ...

Medincell (Paris:MEDCL): This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) and Medincell (MEDCL) announced that the FDA has accepted their supplemental New Drug Application, or sNDA, for UZEDY extended-release ...

Funds raised will enable Medincell to strengthen licensing opportunities by expanding BEPO® technology’s reach into new molecules and indications, and potentially by potentially considering ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...